Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
5.1
Journals
Cells
Special Issues
Onco-Hematology and Immunotherapy
share announcement

Onco-Hematology and Immunotherapy

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 4123

Special Issue Editors

Prof. Dr. Jean Gabert

E-Mail Website
Guest Editor
Unité de Neurobiologie des Canaux Ioniques et de la Synapse, Marseille, France
Interests: leukemia; molecular biology; oncology
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Régis T. Costello

E-Mail Website
Guest Editor
AP-HM Assistance Publique—Hôpitaux de Marseille, Marseille, France
Interests: cancer biology; molecular biology; T lymphocytes; immune response; cytokines; next generation sequencing; gene regulation; lymphoma; transcriptomics; flow cytometry

Special Issue Information

Dear Colleagues,

Leukemias and lymphomas are deadly cancers that mainly affect adults, but leukemias are the second most frequent cancer among children. Today, adult and children with different diseases are treated with different protocols.

New treatments are warranted, and, recently, immunotherapy has appeared as an efficient new tool. Cancers (in general) and onco-hematology (in particular) escape the normal immune control. So, on one side, a better understanding of this phenomenon is required; on the other side, immunotherapy in leukemias aims to boost the immune system in order to fight against cancer cells (leukemias or lymphomas in onco-hematology). The main tools are T cells and antibodies, but trials are also in progress with immune check point inhibitors, leukemia and lymphoma vaccines, and immunomodulators. Allograft in chronic myeloid leukemia is certainly the first example, followed by T cell infusions after allogeneic bone marrow transplantation. The main problems are to understand the normal immune control and its escape in the case of leukemia and lymphomas, as well as to identify the right patients who will benefit from these treatments. So, it is clearly a vast area of research and is also a very promising new tool for precision medicine which could be associated with new or hold drugs.

Prof. Dr. Jean Gabert
Prof. Dr. Régis T. Costello
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • onco-hematology
  • CAR T cells
  • NK cells
  • immune system
  • immune cells
  • leukemias
  • lymphomas

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 6154 KiB  
Article
Immunophenotyping of Peripheral Blood Cells in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
by Pierre Stéphan, Khaled Bouherrou, Yann Guillermin, Anne-Sophie Michallet and Yenkel Grinberg-Bleyer
Cells 2024, 13(17), 1458; https://doi.org/10.3390/cells13171458 - 30 Aug 2024
Viewed by 1620
Abstract
Chronic lymphocytic leukemia (CLL) is a B-cell-derived hematologic malignancy whose progression depends on active B-cell receptor (BCR) signaling. Despite the spectacular efficacy of Ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase (BTK), resistance can develop in CLL patients, and alternative therapeutic strategies are [...] Read more.
Chronic lymphocytic leukemia (CLL) is a B-cell-derived hematologic malignancy whose progression depends on active B-cell receptor (BCR) signaling. Despite the spectacular efficacy of Ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase (BTK), resistance can develop in CLL patients, and alternative therapeutic strategies are therefore required. Cancer immunotherapy has revolutionized cancer care and may be an attractive approach in this context. We speculated that characterizing the immune responses of CLL patients may highlight putative immunotherapeutic targets. Here, we used high-dimensional spectral flow cytometry to compare the distribution and phenotype of non-B-cell immune populations in the circulating blood of CLL patients treated with Ibrutinib displaying a complete response or secondary progression. Although no drastic changes were observed in the composition of their immune subsets, the Ibrutinib-resistant group showed increased cycling of CD8+ T cells, leading to their overabundance at the expense of dendritic cells. In addition, the expression of 11 different surface checkpoints was similar regardless of response status. Together, this suggests that CLL relapse upon Ibrutinib treatment may not lead to major alterations in the peripheral immune response. Full article
(This article belongs to the Special Issue Onco-Hematology and Immunotherapy)
►▼ Show Figures

Figure 1

12 pages, 1156 KiB  
Article
Outcome of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma after Different Numbers of Salvage Regimens
by Jacopo Mariotti, Francesca Ricci, Laura Giordano, Daniela Taurino, Barbara Sarina, Chiara De Philippis, Daniele Mannina, Carmelo Carlo-Stella, Stefania Bramanti and Armando Santoro
Cells 2024, 13(2), 118; https://doi.org/10.3390/cells13020118 - 9 Jan 2024
Viewed by 1985
Abstract
The introduction of novel drugs (PD-1 inhibitors and/or brentuximab vedotin) into salvage regimens has improved the response rate and the outcome of patients with relapsed/refractory Hodgkin lymphoma. However, the impact of new drugs on the outcome has not been adequately investigated so [...] Read more.
The introduction of novel drugs (PD-1 inhibitors and/or brentuximab vedotin) into salvage regimens has improved the response rate and the outcome of patients with relapsed/refractory Hodgkin lymphoma. However, the impact of new drugs on the outcome has not been adequately investigated so far. We retrospectively analyzed 42 consecutive patients treated at our institution with high-dose chemotherapy/autologous stem cell transplantation after either one standard chemotherapy represented by BEGEV (n = 28) or >1 salvage therapy (ST) comprising novel drugs (n = 14). With a median follow-up of 24 months, the 2-year cumulative incidence of relapse was similar between the two cohorts: 26% for 1 ST and 18% for >1 ST (p = 0.822). Consistently, overall survival and progression-free survival did not differ among the two groups: 3-year overall survival was 91% and 89% (p = 0.731), respectively, and 3-year progression-free survival was 74% and 83% (p = 0.822) for only one and more than one salvage regimens, respectively. Of note, the post-transplant side effects and engraftment rates were similar between the 1 ST and >1 ST cohorts. In conclusion, consolidation with high-dose chemotherapy/autologous stem cell transplantation is a safe and curative option, even for patients achieving disease response after more than one rescue line of therapy. Full article
(This article belongs to the Special Issue Onco-Hematology and Immunotherapy)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop